C9 Depleted Sera

Normal human serum depleted of complement C9 protein.


Product Specifications

Citations 2
Description

Normal human serum depleted of complement C9 protein.

Storage Store at -70°C or below. Minimize freeze/thaw cycles.
Form

Frozen liquid. 10 mM sodium phosphate, 145 mM NaCl, pH 7.3. No preservative, 0.22 µm filtered.

Concentration >50 mg protein/mL (refer to CoA for lot specific concentration).
Applications

See citations and technical data sheet for application info.

Ordering Information

For Research Use Only. Not for use in diagnostic procedures.
Catalog Number A505
Catalog Number (CE) N/A
Size 1.0 mL
Price (USD) $195.00
Price (EURO) 175,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

Normal human serum depleted of complement C9 protein.

Size 1.0 mL
Storage

Store at -70°C or below. Minimize freeze/thaw cycles.

Form Frozen liquid. 10 mM sodium phosphate, 145 mM NaCl, pH 7.3. No preservative, 0.22 µm filtered.
Concentration >50 mg protein/mL (refer to CoA for lot specific concentration).
Applications See citations and technical data sheet for application info.
Purity No C9 detectable by immunodiffusion.
Source

Normal human serum

Activity >80% versus normal human serum standard.
Molecular Weight N/A
Background

Normal human serum depleted of complement C9 protein by immunoaffinity chromatography. The product is tested for the absence of C9 by functional assays for classical pathway activity and alternative pathway activity and for C9 protein by double immunodiffusion. Note that the C5b678 complex has considerable hemolytic potential without C9 and therefore C9-Dpl is capable of lysing EA and most other cells directly without added C9 if activation is strong enough and if the concentration of depleted serum used is high enough.

Citations

Title Year Applications Sample Species Sample Sample Details

Complement C1q activates tumor suppressor WWOX to induce apoptosis in prostate cancer cells

2009

WB

Cell Culture

DU-145 Cells

The inhibition of several components of terminal complement pathway results in C3 binding to PNH red blood cells

2024

Complement Activation Assay

Human

Red Blood Cells

PNH